| Tera Santistevan, DPM | |
|
400 S. Mission St., Sapulpa, OK 74066 | |
| (918) 494-2902 | |
| (918) 494-2905 |
| Full Name | Tera Santistevan |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 6 Years |
| Location | 400 S. Mission St., Sapulpa, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588174841 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 368 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metro Tulsa Foot And Ankle Specialist Pllc | 1759293046 | 10 |
News Archive
A new study supports the theory that the detrimental effects of low-level exposure to mercury may be outweighed by the beneficial effects of fish consumption.
Not all patients with blood clots in their legs – a condition known as deep vein thrombosis – need to receive powerful but risky clot-busting drugs, according to results of a large-scale, multicenter clinical trial.
Babies treated for symptomatic cytomegalovirus (CMV) infection for six months, instead of the standard six weeks, have better hearing and developmental outcomes, according to a new study from the University of Alabama at Birmingham.
By increasing production of a blood pressure-regulating enzyme in mice, researchers have found they can enhance the mouse immune system's ability to sense tumor growth.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. In connection with the closing, the Company issued approximately 10.0 million shares of its convertible preferred stock and warrants to purchase approximately 5.0 million shares of its common stock at an exercise price of $1.00 per share.
› Verified 2 days ago
| Provider Name | Metro Tulsa Foot & Ankle Specialist Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1477588945 PECOS PAC ID: 1759293046 Enrollment ID: O20031104000660 |
News Archive
A new study supports the theory that the detrimental effects of low-level exposure to mercury may be outweighed by the beneficial effects of fish consumption.
Not all patients with blood clots in their legs – a condition known as deep vein thrombosis – need to receive powerful but risky clot-busting drugs, according to results of a large-scale, multicenter clinical trial.
Babies treated for symptomatic cytomegalovirus (CMV) infection for six months, instead of the standard six weeks, have better hearing and developmental outcomes, according to a new study from the University of Alabama at Birmingham.
By increasing production of a blood pressure-regulating enzyme in mice, researchers have found they can enhance the mouse immune system's ability to sense tumor growth.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. In connection with the closing, the Company issued approximately 10.0 million shares of its convertible preferred stock and warrants to purchase approximately 5.0 million shares of its common stock at an exercise price of $1.00 per share.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tera Santistevan, DPM 701 W. Elgin St., Broken Arrow, OK 74012 Ph: (918) 494-2902 | Tera Santistevan, DPM 400 S. Mission St., Sapulpa, OK 74066 Ph: (918) 494-2902 |
News Archive
A new study supports the theory that the detrimental effects of low-level exposure to mercury may be outweighed by the beneficial effects of fish consumption.
Not all patients with blood clots in their legs – a condition known as deep vein thrombosis – need to receive powerful but risky clot-busting drugs, according to results of a large-scale, multicenter clinical trial.
Babies treated for symptomatic cytomegalovirus (CMV) infection for six months, instead of the standard six weeks, have better hearing and developmental outcomes, according to a new study from the University of Alabama at Birmingham.
By increasing production of a blood pressure-regulating enzyme in mice, researchers have found they can enhance the mouse immune system's ability to sense tumor growth.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. In connection with the closing, the Company issued approximately 10.0 million shares of its convertible preferred stock and warrants to purchase approximately 5.0 million shares of its common stock at an exercise price of $1.00 per share.
› Verified 2 days ago
Metro Tulsa Foot & Ankle Specialist Pllc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 400 S Mission St, Sapulpa, OK 74066 Phone: 918-224-1881 Fax: 918-224-2108 |